Core Viewpoint - A class action lawsuit has been filed against UroGen Pharma Ltd. for alleged misleading statements regarding its lead product UGN-102, which is intended to treat low-grade intermediate risk non-muscle invasive bladder cancer [1][2][3]. Company Overview - UroGen Pharma Ltd. focuses on developing and commercializing solutions for specialty cancers, with its primary product being UGN-102, an intravesical solution for bladder cancer treatment [2]. Allegations in the Lawsuit - The lawsuit claims that UroGen made false statements and failed to disclose critical information about the ENVISION clinical study for UGN-102, including: - The study was not designed to provide substantial evidence of effectiveness due to the absence of a concurrent control arm [3]. - UroGen faced challenges in demonstrating that the duration of response was attributable to UGN-102 [3]. - The company ignored FDA warnings regarding the study design for the new drug application (NDA) [3]. - There was a significant risk that the NDA for UGN-102 would not receive approval [3]. Impact of FDA Findings - On May 16, 2025, the FDA released a briefing document indicating concerns about the ENVISION study's design, stating that the primary endpoints were difficult to interpret due to the lack of a concurrent control arm. This led to a nearly 26% drop in UroGen's stock price [4]. - Following the FDA's Oncologic Drugs Advisory Committee vote against the NDA for UGN-102 on May 21, 2025, citing unfavorable benefit-risk assessment, UroGen's stock price fell nearly 45% [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Red Cat (RCAT) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockhol ...

Core Viewpoint - A securities class action lawsuit has been filed against Red Cat Holdings, Inc. for alleged misrepresentations regarding its production capacity and contract value, leading to significant financial harm for investors [1][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all persons or entities who purchased Red Cat securities [1]. - The class period for the lawsuit is from March 18, 2022, to January 15, 2025, with a lead plaintiff deadline of July 22, 2025 [7]. - Allegations include misrepresentations about the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract with the U.S. Department of Defense [7]. Group 2: Key Events Timeline - On July 27, 2023, Red Cat disclosed that the Salt Lake City Facility could only produce 100 drones per month, leading to an 8.93% stock drop to $1.02 on July 28, 2023 [7]. - On September 23, 2024, the company reported a Q1 FY2025 loss of $0.17 per share and revenue of $2.8 million, resulting in a 25.32% stock decline to $2.36 on September 25, 2024 [7]. - On November 19, 2024, Red Cat announced winning the SRR Contract, claiming potential revenues of $50–79.5 million for FY2025 [7]. - On January 16, 2025, a report from Kerrisdale Capital estimated the SRR Contract value at $20–25 million, causing the stock to fall 21.54% to $8.56 on January 17, 2025 [7]. Group 3: Impact of Allegations - The lawsuit claims that investors suffered significant financial harm due to alleged false or misleading statements made by Red Cat [7]. - Stock price declines are linked to corrective disclosures regarding the company's production capabilities and contract valuations [7].

PHILADELPHIA, July 15, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company"). The case was filed in the U.S. District Court for the District of New Jersey and alleges that the Company misled investors regarding critical safety disclosures tied to its RP-A501 gene therapy program ...

ATLANTA, July 15, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information regarding Biohaven’s business, operations, and prospects, including allegations that: (i) troriluzole’s regulatory prospects as a treatment for spinocerebellar ataxia, and/or the sufficiency of data that Biohave ...

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Connecticut on behalf of all persons or entities who purchased or otherwise acquired Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN) securities between March 24, 2023 and May 14, 2025, both dates inclusive (the “Class Period”). The Complaint alleges that Defendants made false and/or misleading statements and/or ...

Core Viewpoint - The Schall Law Firm is investigating Harrow, Inc. for potential violations of securities laws related to misleading statements and undisclosed information affecting investors [1][2]. Financial Performance - Harrow, Inc. reported Q1 2025 financial results on May 8, 2025, with revenues that fell short of consensus estimates and an adjusted EBITDA of -$1.9 million [2]. - Following the announcement of these results, Harrow's shares experienced a decline of over 4% [2].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LL ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Petco To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Petco between January 14, 2021 and June 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Centene To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Centene between December 12, 2024 and June 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 15, 2025 /PRNewswire/ -- Faruqi & Faruqi ...